6533b7d5fe1ef96bd12648c1
RESEARCH PRODUCT
Comment on “Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab”
Gabriela G A NaufalPaulo Ricardo CriadoThais A YoshimotoBeatrice Martinez Zugaib AbdallaRoberta F. J. CriadoThais P. Pincellisubject
medicine.medical_specialty2019-20 coronavirus outbreakUrticariaCoronavirus disease 2019 (COVID-19)ExacerbationSARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Symptom Flare UpTreatment outcomeMEDLINECOVID-19OmalizumabDermatologyOmalizumabInternal medicineAnti-Allergic AgentsCorrespondenceHumansMedicineChronic Urticariabusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2020-08-17 | International Journal of Dermatology |